title: Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive.
abstract: BACKGROUND
  Fluocinolone acetonide 0.01% in a blend of refined peanut and mineral oils has been used as treatment for scalp psoriasis for several years, but only more recently for atopic dermatitis.
  
  
  OBJECTIVE
  We sought to study the effectiveness for atopic dermatitis, potential for adrenal axis suppression, and safety of the fluocinolone acetonide 0.01% in oil in children with atopic dermatitis, including children with atopic dermatitis and peanut allergic sensitivity.
  
  
  METHODS
  Three separate studies were performed in children aged 2 to 12 years with atopic dermatitis: multicenter double-blind, randomized, and vehicle-controlled trial; cortisol stimulation testing; and prick testing, patch testing, and monitored medication use in children with peanut allergic sensitivity.
  
  
  RESULTS
  Improvement of >/=50% was demonstrated within 2 weeks in 81% to 87% of 81 patients treated with active medication versus 39% of 45 children treated with vehicle oil alone. No adrenal suppression occurred after 4 weeks of therapy in 32 patients. None of 9 patients who were peanut sensitive reacted to either the full formulation or vehicle in prick or patch testing; 20 children who were peanut sensitive showed no allergic reactions after application of the medication.
  
  
  CONCLUSIONS
  Fluocinolone 0.01% in peanut oil is an effective alternative to the use of topical corticosteroid agents in ointment, cream, and lotion forms in children. No evidence of adrenal suppression or adverse local effects were demonstrated in these studies. The medication was well tolerated in patients with peanut allergic sensitivity.
authors.affiliation: Department of Pediatrics, Children's Memorial Hospital, Northwestern University Medical Center, USA. apaller@northwestern.edu
authors.forename: Amy S
authors.initials: AS
authors.lastname: Paller
authors.forename: Sai
authors.initials: S
authors.lastname: Nimmagadda
authors.forename: Lawrence
authors.initials: L
authors.lastname: Schachner
authors.forename: Susan B
authors.initials: SB
authors.lastname: Mallory
authors.forename: Teri
authors.initials: T
authors.lastname: Kahn
authors.forename: Isaac
authors.initials: I
authors.lastname: Willis
authors.forename: Lawrence F
authors.initials: LF
authors.lastname: Eichenfield
mesh_terms: D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010367:Arachis; D002648:Child; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D021183:Peanut Hypersensitivity / Q000150:complications*; D000074241:Peanut Oil; D014677:Pharmaceutical Vehicles; D010938:Plant Oils
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D000074241:Peanut Oil; D014677:Pharmaceutical Vehicles; D010938:Plant Oils; D005446:Fluocinolone Acetonide